title: Immunotherapy for ovarian cancer.
abstract: All work referenced herein relates to treatment of epithelial ovarian carcinomas, as their treatment differs from ovarian germ cell cancers and other rare ovarian cancers, the treatments of which are addressed elsewhere. Fallopian tube cancers and primary peritoneal adenocarcinomatosis are also generally treated as epithelial ovarian cancers. The standard of care initial treatment of advanced stage epithelial ovarian cancer is optimal debulking surgery as feasible plus chemotherapy with a platinum plus a taxane agent. If this front-line approach fails, as it too often the case, several FDA-approved agents are available for salvage therapy. However, because no second-line therapy for advanced-stage epithelial ovarian cancer is typically curative, we prefer referral to clinical trials as logistically feasible, even if it means referring patients outside our system. Immune therapy has a sound theoretical basis for treating carcinomas generally, and for treating ovarian cancer in particular. Advances in understanding the immunopathogenic basis of ovarian cancer, and the immunopathologic basis for prior failures of immunotherapy for it and other carcinomas promises to afford novel treatment approaches with potential for significant efficacy, and reduced toxicities compared with cytotoxic agents. Thus, referral to early phase immunotherapy trials for ovarian cancer patients that fail conventional treatment merits consideration.
authors: Department of Cellular and Structural Biology, School of Medicine, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
authors: Justin M
authors: JM
authors: Drerup
authors: Yang
authors: Y
authors: Liu
authors: Alvaro S
authors: AS
authors: Padron
authors: Kruthi
authors: K
authors: Murthy
authors: Vincent
authors: V
authors: Hurez
authors: Bin
authors: B
authors: Zhang
authors: Tyler J
authors: TJ
authors: Curiel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents
references: Biologics. 2014 Feb 10;8:27-38
references: 24596453
references: Expert Opin Biol Ther. 2011 Mar;11(3):395-403
references: 21241213
references: Vaccine. 2013 Sep 6;31(39):4252-8
references: 23726825
references: N Engl J Med. 2003 Jan 16;348(3):203-13
references: 12529460
references: Expert Opin Biol Ther. 2012 Feb;12(2):251-7
references: 22192080
references: Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):432-6
references: 7831305
references: J Transl Med. 2006 Apr 07;4:16
references: 16603073
references: Int J Cancer. 2012 Jan 1;130(1):105-12
references: 21328579
references: Blood. 2005 Sep 15;106(6):2018-25
references: 15914560
references: Trends Mol Med. 2008 Apr;14(4):141-51
references: 18353726
references: Cancer Res. 2002 Mar 15;62(6):1696-701
references: 11912142
references: Cancer Immunol Immunother. 2010 Feb;59(2):293-301
references: 19690855
references: Eur J Gynaecol Oncol. 1998;19(2):113-9
references: 9611047
references: Immunity. 2013 Jul 25;39(1):38-48
references: 23890062
references: Biotherapy. 1992;5(4):275-80
references: 1290723
references: Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
references: 8552591
references: J Clin Oncol. 2013 Apr 20;31(12):1554-61
references: 23478059
references: Cancer Immunol Immunother. 2012 Mar;61(3):373-84
references: 21927947
references: Vaccine. 2009 Mar 13;27(12):1825-33
references: 19201387
references: Curr Med Chem. 2010;17(29):3297-302
references: 20712575
references: Clin Cancer Res. 2008 May 15;14(10):3060-9
references: 18483372
references: Bone Marrow Transplant. 2002 Nov;30(9):571-8
references: 12407431
references: J Transl Med. 2012;10:157
references: 22863016
references: Oncoimmunology. 2013 Jan 1;2(1):e22664
references: 23482679
references: Am J Obstet Gynecol. 2013 Nov;209(5):409-14
references: 23583217
references: Cancer Res. 2010 Mar 15;70(6):2245-55
references: 20179192
references: Clin Cancer Res. 2011 Nov 15;17(22):7164-73
references: 22068656
references: Nat Med. 2004 Sep;10(9):942-9
references: 15322536
references: J Clin Oncol. 2009 Jan 20;27(3):418-25
references: 19075271
references: Immunol Rev. 2004 Dec;202:8-32
references: 15546383
references: Hybridoma. 1997 Feb;16(1):41-5
references: 9085127
references: Clin Cancer Res. 2010 Nov 1;16(21):5288-95
references: 20855460
references: Obstet Gynecol. 1990 Jun;75(6):1032-6
references: 2342728
references: J Transl Med. 2013;11:215
references: 24044888
references: Int J Gynecol Cancer. 2000 Jan;10(S1):44-46
references: 11240732
references: Clin Obstet Gynecol. 2012 Mar;55(1):96-113
references: 22343232
references: Cell Mol Immunol. 2015 Jan;12(1):87-95
references: 24976269
references: J Clin Oncol. 1996 Feb;14(2):343-50
references: 8636742
references: J Immunother. 2012 Feb-Mar;35(2):196-204
references: 22306908
references: Gynecol Oncol. 2013 Jun;129(3):452-8
references: 23474348
references: Semin Oncol. 2002 Jun;29(3 Suppl 7):18-26
references: 12068384
references: Eur J Cancer. 1994;30A(3):363-9
references: 8204360
references: J Immunol. 2000 Aug 1;165(3):1705-11
references: 10903782
references: Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1023-34
references: 16343178
references: Expert Opin Biol Ther. 2004 Jul;4(7):1159-65
references: 15268682
references: Hybridoma. 1997 Feb;16(1):33-40
references: 9085126
references: Int J Gynecol Cancer. 2002 Jan-Feb;12(1):80-5
references: 11860540
references: Cancer Res. 2012 Apr 15;72(8):2089-99
references: 22496463
references: Clin Cancer Res. 2002 May;8(5):1014-8
references: 12006513
references: J Clin Oncol. 1987 Dec;5(12):1890-9
references: 3681374
references: Clin Cancer Res. 2008 May 1;14(9):2740-8
references: 18451240
references: J Immunol. 2010 Sep 1;185(5):2747-53
references: 20686128
references: Nat Med. 2003 May;9(5):562-7
references: 12704383
references: Clin Cancer Res. 2011 Sep 15;17(18):6083-96
references: 21795409
references: Cancer Immunol Res. 2013 Sep;1(3):168-78
references: 24777679
references: Clin Cancer Res. 2002 Jul;8(7):2413-22
references: 12114447
references: Cancer. 1989 Sep 1;64(5):1029-33
references: 2758381
references: Gynecol Oncol. 2010 Feb;116(2):202-7
references: 19880164
references: J Clin Oncol. 2002 Jun 1;20(11):2624-32
references: 12039923
references: J Exp Med. 2006 Apr 17;203(4):871-81
references: 16606666
references: Nat Rev Cancer. 2012 Apr;12(4):252-64
references: 22437870
references: Cancer Immunol Immunother. 2012 May;61(5):629-41
references: 22021066
references: J Clin Oncol. 2013 Aug 10;31(23):2970
references: 23816970
references: Clin Cancer Res. 2000 Jun;6(6):2268-78
references: 10873077
references: Clin Cancer Res. 2010 Dec 15;16(24):6132-8
references: 21037025
references: PLoS One. 2013;8(12):e84927
references: 24367702
references: Semin Immunol. 2014 Feb;26(1):54-74
references: 24552665
references: Cancer J. 2014 Mar-Apr;20(2):119-22
references: 24667956
references: Gynecol Oncol. 2011 May 1;121(2):273-9
references: 21276608
references: J Immunother. 1999 Jan;22(1):54-66
references: 9924700
references: Cancer Res. 2008 Jul 15;68(14):5658-68
references: 18632618
references: Cancer Res. 2007 Aug 1;67(15):7487-94
references: 17671219
references: J Clin Invest. 2013 Jul;123(7):2756-63
references: 23863633
references: Gynecol Oncol. 2012 May;125(2):441-50
references: 22306204
references: Br J Cancer. 2000 Mar;82(6):1138-44
references: 10735496
references: Nat Rev Cancer. 2012 Apr;12(4):278-87
references: 22437872
references: Int J Cancer. 2014 Mar 1;134(5):1091-101
references: 23982804
references: Mol Cancer Ther. 2012 May;11(5):1062-70
references: 22532596
references: Clin Cancer Res. 2006 Sep 15;12(18):5503-10
references: 17000686
references: Cancer Immunol Res. 2014 Jan;2(1):37-49
references: 24535937
references: Cancer Res. 1992 Oct 1;52(19):5416-20
references: 1394148
references: J Clin Oncol. 1990 Dec;8(12):1941-50
references: 2230887
references: Oncol Rep. 2006 Jul;16(1):141-6
references: 16786137
references: Cancer. 1993 Mar 15;71(6):2027-30
references: 7680276
references: J Natl Cancer Inst. 1986 Jun;76(6):995-1006
references: 3520078
references: Br J Cancer. 1993 Aug;68(2):403-6
references: 8347497
references: Crit Rev Oncol Hematol. 2014 Jan;89(1):129-39
references: 24029605
references: Cancer Res. 1990 Nov 1;50(21):7037-41
references: 2119884
references: Med Oncol. 2014 Aug;31(8):76
references: 24965536
references: Br J Cancer. 2012 Jun 26;107(1):37-42
references: 22644293
references: Int J Rad Appl Instrum B. 1989;16(6):659-66
references: 2606721
references: Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42
references: 15217923
references: Eur J Cancer. 1997 Jun;33(7):1114-21
references: 9376192
references: Int J Cancer. 2007 Jun 15;120(12):2710-4
references: 17354223
references: Hum Vaccin Immunother. 2014;10(2):338-43
references: 24252799
references: Immunity. 2013 Jul 25;39(1):49-60
references: 23890063
references: J Clin Oncol. 1990 Jun;8(6):1036-41
references: 2189953
references: Gynecol Oncol. 2005 Nov;99(2):462-71
references: 16137749
references: Scand J Immunol. 1993 Apr;37(4):413-24
references: 8469924
references: Cancer Res. 2010 Apr 15;70(8):3052-61
references: 20388795
references: Cancer Immunol Immunother. 2005 Dec;54(12):1200-13
references: 15926078
references: Adv Immunol. 2004;82:249-93
references: 14975259
references: Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5797-802
references: 22454499
references: N Engl J Med. 2012 Jun 28;366(26):2455-65
references: 22658128
references: Br J Cancer. 2009 Apr 7;100(7):1144-53
references: 19293794
references: Cancer Res. 1985 Sep;45(9):4447-53
references: 4028027
references: Immunol Cell Biol. 2013 Jul;91(6):435-40
references: 23628805
references: Mol Ther. 2010 Apr;18(4):852-60
references: 20068553